Background and aim
Edited by: Antonio Di Sabatino, University of Pavia, ItalyReviewed by: Mitsushige Sugimoto, Tokyo Medical University Hospital, Japan; Anna Katrina Walduck, RMIT University, Australia†These authors have contributed equally to this work and share first authorship‡These authors have contributed equally to this work and share last authorshipThis article was submitted to Mucosal Immunity, a section of the journal Frontiers in ImmunologyWe previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for 